Luschnig Petra, Schicho Rudolf
Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz, Graz, Austria.
Med Cannabis Cannabinoids. 2019 May 24;2(1):14-21. doi: 10.1159/000499164. eCollection 2019 Sep.
The endocannabinoid system (ECS) is a multifunctional homeostatic system involved in many physiological and pathological conditions. The ligands of the ECS are the endo-cannabinoids, whose actions are mimicked by exogenous cannabinoids, such as phytocannabinoids and synthetic cannabinoids. Responses to the ligands of the ECS are mediated by numerous receptors like the classical cannabinoid receptors (CB and CB) as well as ECS-related receptors, e.g., G protein-coupled receptors 18 and 55 (GPR18 and GPR55), transient receptor potential ion channels, and nuclear peroxisome proliferator-activated receptors. The ECS regulates almost all levels of female reproduction, starting with oocyte production through to parturition. Dysregulation of the ECS is associated with the development of gynecological disorders from fertility disorders to cancer. Cannabinoids that act at the ECS as specific agonists or antagonists may potentially influence dysregulation and, therefore, represent new therapeutic options for the therapy of gynecological disorders.
内源性大麻素系统(ECS)是一个多功能的稳态系统,参与许多生理和病理过程。ECS的配体是内源性大麻素,其作用可被外源性大麻素模拟,如植物大麻素和合成大麻素。对ECS配体的反应由众多受体介导,如经典大麻素受体(CB1和CB2)以及ECS相关受体,例如G蛋白偶联受体18和55(GPR18和GPR55)、瞬时受体电位离子通道和核过氧化物酶体增殖物激活受体。ECS几乎调节女性生殖的所有阶段,从卵母细胞产生到分娩。ECS失调与从生育障碍到癌症等妇科疾病的发生有关。作为特异性激动剂或拮抗剂作用于ECS的大麻素可能会影响失调情况,因此代表了治疗妇科疾病的新治疗选择。